<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiological adverse events after oncological treatment are related to given drugs and patients </plain></SENT>
<SENT sid="1" pm="."><plain>Cardiotoxicity is more often observed in the female population </plain></SENT>
<SENT sid="2" pm="."><plain>The reason for this phenomenon is unknown </plain></SENT>
<SENT sid="3" pm="."><plain>There are no differences in mechanism and duration of cardiotoxicity between men and women </plain></SENT>
<SENT sid="4" pm="."><plain>Temporary dysrhythmia, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> are the most often adverse effects after oncological treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Pathomechanism of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is related to the presence of free radicals </plain></SENT>
<SENT sid="6" pm="."><plain>Prevention against cardiological adverse effects is very important because of the limited options to reverse them </plain></SENT>
<SENT sid="7" pm="."><plain>Prevention includes not exceeding the cumulative dose, the <z:chebi fb="0" ids="48120">anthracycline</z:chebi> dose fractionation, adequate qualification for cardiotoxic treatment, liposomal <z:chebi fb="0" ids="28748">doxorubicins</z:chebi> use or dextrasoxane administration to restrict free radicals </plain></SENT>
</text></document>